Mediolanum International Funds Ltd Increases Stock Position in Johnson & Johnson $JNJ

Mediolanum International Funds Ltd increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 14.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 426,141 shares of the company’s stock after purchasing an additional 52,199 shares during the quarter. Johnson & Johnson makes up about 0.8% of Mediolanum International Funds Ltd’s holdings, making the stock its 20th biggest position. Mediolanum International Funds Ltd’s holdings in Johnson & Johnson were worth $64,948,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clark Asset Management LLC lifted its position in shares of Johnson & Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after buying an additional 3,025 shares during the last quarter. Apexium Financial LP raised its stake in Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares during the period. Avanza Fonder AB lifted its holdings in Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after purchasing an additional 4,816 shares during the period. Finally, Klingman & Associates LLC increased its stake in shares of Johnson & Johnson by 13.4% in the first quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock worth $2,817,000 after purchasing an additional 2,005 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. UBS Group boosted their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Finally, Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $201.05.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $203.29 on Friday. The firm has a market capitalization of $489.77 billion, a P/E ratio of 19.62, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $187.74 and its two-hundred day simple moving average is $171.22. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $204.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.